Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Jaen

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1993
Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomersL T Meltzer, B W Caprathe, C L Christoffersen, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r proteaseJ S Plummer, C Cai, S J Hays, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Novel antineoplastic agents with efficacy against multidrug resistant tumor cellsJ C Medina, B Shan, H Beckmann, et al.
Journal of Medicinal Chemistry|April 17, 1998
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine proteaseS J Hays, B W Caprathe, J L Gilmore, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 1999
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumorsB Shan, J C Medina, E Santha, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical doseD J Dairaghi, P Zhang, Y Wang, et al.
Pharmaceutica Acta Helvetiae|May 17, 2000
CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacologyH Tecle, R D Schwarz, S D Barrett, et al.
Journal of Medicinal Chemistry|July 3, 1998
Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonistH Tecle, S D Barrett, D J Lauffer, et al.
British Journal of Cancer|January 16, 2014
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and ratsM J Walters, K Ebsworth, R D Berahovich, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1993
Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomersL T Meltzer, B W Caprathe, C L Christoffersen, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Benzenesulfonamide derivatives of 2-substituted 4H-3,1-benzoxazin-4-ones and benzthiazin-4-ones as inhibitors of complement C1r proteaseJ S Plummer, C Cai, S J Hays, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Novel antineoplastic agents with efficacy against multidrug resistant tumor cellsJ C Medina, B Shan, H Beckmann, et al.
Journal of Medicinal Chemistry|April 17, 1998
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine proteaseS J Hays, B W Caprathe, J L Gilmore, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 1999
Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumorsB Shan, J C Medina, E Santha, et al.
Clinical Pharmacology and Therapeutics|April 1, 2011
Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical doseD J Dairaghi, P Zhang, Y Wang, et al.
Pharmaceutica Acta Helvetiae|May 17, 2000
CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacologyH Tecle, R D Schwarz, S D Barrett, et al.
Journal of Medicinal Chemistry|July 3, 1998
Design and synthesis of m1-selective muscarinic agonists: (R)-(-)-(Z)-1-Azabicyclo[2.2.1]heptan-3-one, O-(3-(3'-methoxyphenyl)-2-propynyl)oxime maleate (CI-1017), a functionally m1-selective muscarinic agonistH Tecle, S D Barrett, D J Lauffer, et al.
British Journal of Cancer|January 16, 2014
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and ratsM J Walters, K Ebsworth, R D Berahovich, et al.
Pageof 3